Cardioplegic solution perfusion monitoring device and monitoring method

Abstract

The application discloses a kind of cardioplegic solution perfusion monitoring device and monitoring method, it is related to medical instrument technical field.The device includes cardioplegic solution perfusion pipeline, cardioplegic solution backflow pipeline, membrane oxygenator, first detection sensor and second detection sensor;The input end of cardioplegic solution perfusion pipeline is suitable for being introduced into cardioplegic solution, and the output end of cardioplegic solution perfusion pipeline is suitable for being inserted in heart;The input end of cardioplegic solution backflow pipeline is suitable for being communicated with heart chamber;The output end of cardioplegic solution backflow pipeline is communicated with membrane oxygenator;First detection sensor is arranged on cardioplegic solution perfusion pipeline, and first detection sensor is used to detect the composition of cardioplegic solution transported to heart;Second detection sensor is arranged on cardioplegic solution backflow pipeline, and second detection sensor is used to detect the composition of cardioplegic solution extracted backflow by heart chamber.The application provides a kind of cardioplegic solution perfusion monitoring device and monitoring method, realizes the monitoring of cardioplegic solution composition, is helpful to improve myocardial protection effect and reduce the risk of postoperative complication of heart.

Description

Technical Field

[0001] This invention relates to the field of medical device technology, and in particular to a device and method for monitoring the perfusion of stop-flow fluid. Background Technology

[0002] Currently, there are still some details in cardiopulmonary bypass surgery that need improvement, such as myocardial protection, which is a very important aspect and largely determines the success or failure of the surgery.

[0003] Cardiac arrest fluid infusion is a crucial aspect of myocardial protection and a core technology of cardiopulmonary bypass. Currently, most cardiac arrest fluids used clinically are prepared on an ad-hoc basis. Improper storage of commercially available cardiac arrest fluids can lead to changes in their composition, resulting in reduced myocardial protective efficacy and increased risk of postoperative cardiac complications.

[0004] The existing perfusion device includes a first drive pump and a second drive pump; one end of the first drive pump is connected to the output end of the first infusion tube, and the input end of the first infusion tube is connected to the oxygenation blood interface of the membrane lung; the other end of the first drive pump is connected to the input end of the second infusion tube, and the output end of the second infusion tube is connected to the perfusion tube, the perfusion end of the perfusion tube being inserted into the target perfusion site; one end of the second drive pump is connected to the output end of the third infusion tube, and the input end of the third infusion tube is connected to the stop-flow fluid container; the other end of the first drive pump is connected to the input end of the fourth infusion tube, and the output end of the fourth infusion tube is connected to the perfusion tube.

[0005] However, when using this infusion device, the infusion technician cannot know whether the composition of the stop fluid has changed, which poses a potential risk. Summary of the Invention

[0006] The main objective of this invention is to provide a device and method for monitoring the perfusion of cardioplegic solution, which aims to monitor the components of cardioplegic solution in order to improve the myocardial protection effect and reduce the risk of postoperative complications after cardiac surgery.

[0007] To achieve the above objectives, the present invention proposes a stop-jump fluid perfusion monitoring device, the stop-jump fluid perfusion monitoring device comprising: A cardioplegic solution infusion line, wherein the inlet of the cardioplegic solution infusion line is adapted to receive cardioplegic solution, and the outlet of the cardioplegic solution infusion line is adapted to be inserted into the heart; A stop-pump fluid return line, wherein the input end of the stop-pump fluid return line is adapted to communicate with the heart chamber; A membrane oxygenator, wherein the output end of the stop-shutdown fluid return line is connected to the membrane oxygenator; A first detection sensor is disposed on the cardioplegic solution infusion line, and the first detection sensor is used to detect the components of the cardioplegic solution delivered to the heart; and The second detection sensor is located on the stop-beat fluid return line and is used to detect the components of the stop-beat fluid drained from the heart chambers.

[0008] Optionally, the stop-jump fluid infusion monitoring device further includes a first display, which is electrically connected to the first detection sensor and is used to display stop-jump fluid composition information.

[0009] Optionally, the stop-jump fluid infusion monitoring device further includes a second display, which is electrically connected to the second detection sensor and is used to display stop-jump fluid composition information.

[0010] Optionally, the stop-jump fluid return line includes a return conduit and a balloon disposed at the input end of the return conduit, the balloon being used to prevent blood from flowing out of the coronary sinus.

[0011] Optionally, the reflux conduit is provided with a reflux channel and an inflation channel separated from the reflux channel, the distal end of the inflation channel communicating with the balloon, and the proximal end of the inflation channel being adapted to introduce fluid; or The stop-jump fluid return line also includes a filling conduit, which is disposed close to the return conduit. The distal end of the filling conduit is connected to the balloon, and the proximal end of the filling conduit is adapted to allow fluid to enter.

[0012] Optionally, the stop-jump fluid return line may further include a fluid container connected to the filling channel or the filling conduit.

[0013] Optionally, both the first detection sensor and the second detection sensor are blood gas monitors.

[0014] Optionally, the stop-jump fluid injection monitoring device further includes a temperature controller, which is located on the stop-jump fluid injection pipeline and is used to adjust the temperature of the stop-jump fluid.

[0015] Optionally, the stop-jump fluid infusion monitoring device further includes a peristaltic pump, which is located on the stop-jump fluid infusion pipeline and is used to drive the flow of the stop-jump fluid.

[0016] To achieve the above objectives, the present invention also proposes a monitoring method for a stop-jump fluid infusion monitoring device, wherein the stop-jump fluid infusion monitoring device comprises: A cardioplegic solution infusion line, wherein the inlet of the cardioplegic solution infusion line is adapted to receive cardioplegic solution, and the outlet of the cardioplegic solution infusion line is adapted to be inserted into the heart; A stop-pump fluid return line, wherein the input end of the stop-pump fluid return line is adapted to communicate with the heart chamber; A membrane oxygenator, wherein the output end of the stop-shutdown fluid return line is connected to the membrane oxygenator; A first detection sensor is disposed on the cardioplegic solution infusion line, and the first detection sensor is used to detect the components of the cardioplegic solution delivered to the heart; and The second detection sensor is located on the stop-beat fluid return line and is used to detect the components of the stop-beat fluid drained from the heart chambers. The monitoring method includes the following steps: The composition of the liquid in the stop-jump fluid injection line is detected and generated as the first liquid composition information; The composition of the liquid in the stop-shutdown fluid return line is detected and a second liquid composition information is generated. Compare the first liquid composition information with the second liquid composition information to determine whether at least one of the components of the stop-jump fluid is within the target range value; An alarm signal is output when at least one of the components of the stop-jump fluid is not within the target range.

[0017] In the technical solution of the present invention, the cardioplegic respiration monitoring device includes a cardioplegic respiration line, a cardioplegic respiration line, a membrane oxygenator, a first detection sensor, and a second detection sensor; the input end of the cardioplegic respiration line is adapted to introduce cardioplegic respiration, and the output end of the cardioplegic respiration line is adapted to be inserted into the heart; the input end of the cardioplegic respiration line is adapted to communicate with the heart chamber; the output end of the cardioplegic respiration line is connected to the membrane oxygenator; the first detection sensor is disposed on the cardioplegic respiration line and is used to detect the components of the cardioplegic respiration delivered to the heart; the second detection sensor is disposed on the cardioplegic respiration line and is used to detect the components of the cardioplegic respiration drained and returned from the heart chamber. It is understood that the present invention provides a device and method for monitoring the perfusion of cardioplegic solution. By setting a first detection sensor to detect the components of the cardioplegic solution delivered to the heart, and setting a second detection sensor to detect the components of the cardioplegic solution drained and returned from the heart chambers, the perfusionist can compare the components of the returned cardioplegic solution with the components of the original perfused cardioplegic solution. If the two components are similar, it indicates that the cardioplegic solution is well distributed throughout the myocardium. This achieves the monitoring of the components of the cardioplegic solution, which helps to improve the myocardial protection effect and reduce the risk of postoperative cardiac complications. This scheme is expected to become the standard scheme for monitoring the components of cardioplegic solution for myocardial protection in the future. Attached Figure Description

[0018] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on the structures shown in these drawings without creative effort.

[0019] Figure 1This is a schematic diagram of an embodiment of the stop-jump fluid infusion monitoring device of the present invention; Figure 2 This is a schematic flowchart of an embodiment of the monitoring method of the stop-jump fluid infusion monitoring device of the present invention.

[0020] Explanation of icon numbers: 100, Stop-start fluid injection line; 200, Stop-start fluid return line; 300, Membrane oxygenator; 400, First detection sensor; 500, Second detection sensor; 600, First display; 700, Second display; 210, Return conduit; 220, Balloon; 230, Filling conduit; 240, Fluid container.

[0021] The realization of the objective, functional features and advantages of the present invention will be further explained in conjunction with the embodiments and with reference to the accompanying drawings. Detailed Implementation

[0022] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only a part of the embodiments of the present invention, and not all of them. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative effort are within the scope of protection of the present invention.

[0023] It should be noted that all directional indications (such as up, down, left, right, front, back, etc.) in the embodiments of the present invention are only used to explain the relative positional relationship and movement of each component in a certain specific posture (as shown in the figure). If the specific posture changes, the directional indication will also change accordingly.

[0024] In the description of this invention, it should also be noted that, unless otherwise explicitly specified and limited, the terms "installation," "connection," and "linking" should be interpreted broadly. For example, they can refer to a fixed connection, a detachable connection, or an integral connection; they can refer to a mechanical connection or an electrical connection; they can refer to a direct connection or an indirect connection through an intermediate medium; and they can refer to the internal connection of two components. Those skilled in the art can understand the specific meaning of the above terms in this invention based on the specific circumstances. In the description of this invention, the terms "proximal end" and "distal end" refer to near and far relative to the operator. When using this invention, the end closer to the operator is the "proximal end," that is, the end where the operator is located, and the end farther from the operator is the "distal end."

[0025] Furthermore, the use of terms such as "first" and "second" in this invention is for descriptive purposes only and should not be construed as indicating or implying their relative importance or implicitly specifying the number of technical features indicated. Therefore, a feature defined with "first" or "second" may explicitly or implicitly include at least one of those features. The word "and / or" throughout the text means including three parallel solutions; for example, "A and / or B" includes solution A, solution B, or a solution that simultaneously satisfies A and B. The technical solutions of the various embodiments can be combined with each other, but this must be based on the ability of those skilled in the art to implement them. When the combination of technical solutions is contradictory or impossible to implement, it should be considered that such a combination of technical solutions does not exist and is not within the scope of protection claimed by this invention.

[0026] Currently, there are still some details in cardiopulmonary bypass surgery that need improvement, such as myocardial protection, which is a very important aspect and largely determines the success or failure of the surgery.

[0027] Cardiac arrest fluid infusion is a crucial aspect of myocardial protection and a core technology of cardiopulmonary bypass. Currently, most cardiac arrest fluids used clinically are prepared on an ad-hoc basis. Improper storage of commercially available cardiac arrest fluids can lead to changes in their composition, resulting in reduced myocardial protective efficacy and increased risk of postoperative cardiac complications.

[0028] The existing perfusion device includes a first drive pump and a second drive pump; one end of the first drive pump is connected to the output end of the first infusion tube, and the input end of the first infusion tube is connected to the oxygenation blood interface of the membrane lung; the other end of the first drive pump is connected to the input end of the second infusion tube, and the output end of the second infusion tube is connected to the perfusion tube, the perfusion end of the perfusion tube being inserted into the target perfusion site; one end of the second drive pump is connected to the output end of the third infusion tube, and the input end of the third infusion tube is connected to the stop-flow fluid container; the other end of the first drive pump is connected to the input end of the fourth infusion tube, and the output end of the fourth infusion tube is connected to the perfusion tube.

[0029] However, when using this infusion device, the infusion technician cannot know whether the composition of the stop fluid has changed, which poses a potential risk.

[0030] Based on this, the present invention proposes a stop-jump fluid infusion monitoring device to solve the above problems.

[0031] Reference Figure 1In one embodiment of the present invention, the cardioplegic respiration monitoring device includes a cardioplegic respiration line 100, a cardioplegic respiration line 200, a membrane oxygenator 300, a first detection sensor 400, and a second detection sensor 500. The input end of the cardioplegic respiration line 100 is adapted to receive cardioplegic respiration, and the output end of the cardioplegic respiration line 100 is adapted to be inserted into the heart. The input end of the cardioplegic respiration line 200 is adapted to communicate with the heart chambers. The output end of the cardioplegic respiration line 200 is connected to the membrane oxygenator 300. The first detection sensor 400 is disposed on the cardioplegic respiration line 100 and is used to detect the components of the cardioplegic respiration delivered to the heart. The second detection sensor 500 is disposed on the cardioplegic respiration line 200 and is used to detect the components of the cardioplegic respiration drained and returned from the heart chambers.

[0032] In this embodiment, the cardioplegic solution perfusion line 100 may include at least one main perfusion catheter, the output end of which may be provided with a perfusion needle to facilitate insertion into the heart. In some cases, branch catheters may also be provided for easy connection to other devices; this is not a limitation.

[0033] In this embodiment, the stop-shutdown fluid return line 200 may include at least one main return line and several branch lines, which are not limited here.

[0034] The Membrane Oxygenator 300, also known as a membrane artificial lung, is a medical device that temporarily replaces the function of the human lungs during extracorporeal circulation surgery or life support. It features oxygenation, temperature regulation, blood storage, and filtration functions. Through biomimetic design, it achieves non-direct contact exchange of blood and gases, primarily used in open-heart surgery to replace lung function for blood gas exchange. Its core structure includes an oxygenation chamber and a temperature regulation chamber. The oxygenation chamber achieves efficient gas exchange through a hollow fiber membrane, while the temperature regulation chamber regulates blood temperature through a heat exchanger.

[0035] In this embodiment, both the first detection sensor 400 and the second detection sensor 500 can be blood gas analyzers or other instruments capable of directly or indirectly detecting the components of the cardioplegic fluid; no limitation is made here. The cardioplegic fluid perfusion monitoring device may also include a first display 600 and a second display 700; the first display 600 is electrically connected to the first detection sensor 400 and is used to display cardioplegic fluid component information; the second display 700 is electrically connected to the second detection sensor 500 and is used to display cardioplegic fluid component information. Specifically, the blood gas analyzer can be a CDI550 blood gas analyzer from a certain company. This blood gas analyzer includes a probe part and a display part, that is, it includes a detection sensor and a display, which can not only detect the components of the cardioplegic fluid in real time, but also display key component information through the display.

[0036] It should be noted that the cardioplegic solution used in this embodiment can be a blood-containing cardioplegic solution such as Del Nido cardioplegic solution or Buckberg's cardioplegic solution. The blood-containing cardioplegic solution is a mixture of the patient's own arterial blood and crystalloid fluid in a specific ratio (e.g., 4:1 or 1:4). After mixing, the mixture retains all the characteristics of blood (containing red blood cells and plasma). When this blood-containing cardioplegic solution is infused into the patient, it enters the patient's coronary artery through the cardioplegic solution infusion line 100, and then flows back from the coronary sinus into the cardioplegic solution return line 200 of the extracorporeal circulation system, where it mixes with the venous blood returning from the system. A blood gas monitor can provide the perfusionist with key information about the effects of the blood-containing cardioplegic solution and the myocardial status, indirectly verifying the composition of the actually infused blood-containing cardioplegic solution. The blood gas monitor can also monitor the potassium ion (K) levels in the patient's arterial blood in real time after the infusion of the blood-containing cardioplegic solution. + Concentration changes. Because the blood-containing cardioplegic solution is high in potassium, after perfusion, some potassium ions will flow back into the extracorporeal circulation from the coronary sinus, causing a momentary increase in the potassium concentration in the patient's systemic blood. A blood gas monitor can sensitively detect this increase, thus confirming that the high-potassium cardioplegic solution has indeed been injected into the patient, assessing the retention and metabolism of the cardioplegic solution in the myocardium, and monitoring whether excessive perfusion frequency will lead to systemic hyperkalemia. The blood gas monitor can also continuously monitor parameters such as pH, pCO2, and pO2, reflecting the metabolic state of myocardial tissue after perfusion with the blood-containing cardioplegic solution. For example, an abnormally high pCO2 or a low pH may indicate myocardial ischemia or insufficient perfusion; monitoring changes in oxygen consumption (VO2) and oxygen delivery (DO2) can assess the effectiveness of myocardial protection. This invention, by incorporating a blood gas monitor, can guide perfusionists to adjust perfusion strategies in real time. Based on continuous, real-time feedback from the blood gas monitor, perfusionists can dynamically adjust the timing, flow rate, temperature, or composition of subsequent perfusions, achieving truly goal-oriented perfusion.

[0037] It is understood that the present invention provides a device and method for monitoring the perfusion of cardioplegic solution. By setting a first detection sensor 400 to detect the components of the cardioplegic solution delivered to the heart, and setting a second detection sensor 500 to detect the components of the cardioplegic solution drained and returned from the heart chambers, the perfusionist can compare the components of the returned cardioplegic solution with the components of the original perfused cardioplegic solution. If the two components are similar, it indicates that the cardioplegic solution is well distributed throughout the myocardium. This achieves the monitoring of the components of the cardioplegic solution, which helps to improve the myocardial protection effect and reduce the risk of postoperative complications after heart surgery. This scheme is expected to become the standard scheme for monitoring the components of cardioplegic solution for myocardial protection in the future.

[0038] In one embodiment, reference is made to Figure 1The stop-pump fluid return line 200 may include a return catheter 210 and a balloon 220 disposed at the input end of the return catheter 210. The balloon 220 is used to prevent blood from flowing out of the coronary sinus and to prevent blood from flowing out of the coronary sinus from the periphery of the insertion site of the return catheter 210, thus ensuring the safety of the procedure.

[0039] In this embodiment, the balloon 220 can be an air balloon or a liquid balloon, that is, the balloon 220 can be filled with gas or liquid, which is not limited here.

[0040] In one embodiment, reference is made to Figure 1 The stop-jump fluid infusion monitoring device can adopt a split-type return conduit and filling conduit 230 structure. The stop-jump fluid return line 200 may include the filling conduit 230, which is disposed close to the return conduit 210. The distal end of the filling conduit 230 is connected to the balloon 220, and the proximal end of the filling conduit 230 is suitable for fluid introduction. This embodiment adopts this split-type conduit structure, which makes it easier to lead out the proximal end of the filling conduit 230 for connection to containers such as air bags.

[0041] In this embodiment, the stop-jump fluid return line 200 may further include a fluid container 240 connected to the filling conduit 230 or the filling channel described below. The fluid container 240 may be an air bag or a medicine bag, etc., and is not limited here.

[0042] Of course, in other scenarios, an integrated stop-jump fluid return conduit 210 structure can also be used. The return conduit 210 may have a return channel and a filling channel separated from the return channel. The distal end of the filling channel is connected to the balloon 220, and the proximal end of the filling channel is suitable for fluid introduction. In this embodiment, the return conduit 210 adopts an integrated structure with two channels along its axial direction, one of which is the return channel and the other is the filling channel. This integrated conduit has better overall integrity and a more compact structure.

[0043] Cardiac arrest fluid perfusion is a crucial aspect of myocardial protection and a core technology of cardiopulmonary bypass. The primary goal of cardiac arrest fluid perfusion is to rapidly and uniformly cool the myocardium and achieve cardiac arrest. Myocardial temperature is the most direct physiological indicator of perfusion effectiveness, and the perfusion dose is the means to achieve this goal. In one embodiment, the cardiac arrest fluid perfusion monitoring device may further include a temperature controller, which is located on the cardiac arrest fluid perfusion line 100 and is used to regulate the temperature of the cardiac arrest fluid. This helps to further enhance the myocardial protection effect.

[0044] In this embodiment, the cardioplegic respiration monitoring device may further include a peristaltic pump, which is installed on the cardioplegic respiration line 100 and is used to drive the flow of cardioplegic respiration so that the target dose of cardioplegic respiration can be perfused to the heart at an appropriate time.

[0045] This invention also proposes a monitoring method for a stop-jump fluid infusion monitoring device. This monitoring method is based on the aforementioned stop-jump fluid infusion monitoring device, the specific structure of which is described in the above embodiments. Since the monitoring method proposed in this invention includes all the steps and solutions of all embodiments of the aforementioned stop-jump fluid infusion monitoring device, it has at least the same technical effects as the aforementioned stop-jump fluid infusion monitoring device, which will not be elaborated here.

[0046] Reference Figure 1 and Figure 2 In one embodiment of the present invention, the monitoring method of the stop-jump fluid perfusion monitoring device includes the following steps: S10. Detect the composition of the liquid in the stop-jump fluid injection line 100 and generate the first liquid composition information; S20. Detect the composition of the liquid in the stop fluid return line 200 and generate second liquid composition information; S30. Compare the first liquid composition information with the second liquid composition information to determine whether at least one of the components of the stop-jump fluid is within the target range. S40. When at least one of the components of the stop fluid is not within the target range, an alarm signal is output.

[0047] In this embodiment, a first detection sensor on the cardioplegic solution infusion line 100 detects the components of the cardioplegic solution delivered to the heart and obtains first fluid component information; a second detection sensor 500 on the cardioplegic solution return line 200 detects the components of the cardioplegic solution drained and returned from the heart chambers and obtains second fluid component information. This cardioplegic solution infusion monitoring system, by comparing the first and second fluid component information, can determine whether at least one component of the cardioplegic solution (such as potassium ion concentration) is within a target range. When the comparison value exceeds the target range, an alarm signal can be output through a display, indicator light, or buzzer to alert the perfusionist of an abnormal cardioplegic solution infusion, thereby allowing for timely cessation of infusion or adjustment of the infusion method.

[0048] It should be noted that an imbalance in the composition of the cardioplegic solution can damage the myocardium, primarily due to potassium ions (K). + ) concentration, calcium ions (Ca 2+ Concentration, pH and buffers, and magnesium ions (Mg) 2+ The following is an explanation: (1) When potassium ions (K + An imbalance in potassium concentration can lead to depolarization damage and high-risk cardiac events. High potassium levels are a common clinical problem; while high potassium concentrations can rapidly cause cardiac arrest, persistent cell membrane depolarization can cause serious problems, such as persistent sodium poisoning. + / Ca 2+This exchange process continues, resulting in energy expenditure even after the heart has stopped beating, with adenosine triphosphate (ATP) being continuously wasted. The consequences include mitochondrial damage and cell death, as well as inducing sodium metabolism disorders. + and Ca² + Influx of potassium into the bloodstream leads to cell edema, acidosis, and ultimately triggers programmed cell death. Furthermore, both hyperkalemia and hypokalemia following cardiopulmonary bypass significantly increase the risk of postoperative arrhythmias and myocardial failure. Acute hyperkalemia itself can also cause coronary artery dysfunction, affecting postoperative myocardial blood supply.

[0049] (2) Calcium ions (Ca 2+ Imbalances in calcium concentration can lead to calcium paradoxes and reperfusion injury. Calcium is a key initiator of reperfusion injury. Therefore, low-calcium cardioplegic solutions are widely used clinically to inhibit calcium ion influx and protect mitochondria and cell structure. Calcium-free or high-calcium solutions are harmful; completely calcium-free cardioplegic solutions are less effective, while high calcium concentrations (>1 mM) are equally detrimental. Sudden high calcium supplementation during reperfusion can exacerbate myocardial stunning and mitochondrial dysfunction.

[0050] (3) pH and buffer imbalance may induce acidosis and myocardial stunning. Prolonged ischemia can lead to myocardial acidosis, with pH dropping to a dangerous level of 6.5-6.2. This directly affects Na+. + -Ca² + The exchanger function is impaired, exacerbating intracellular calcium imbalance and damaging left ventricular and microvascular function. The key role of buffering capacity lies in the fact that human blood plasma (pH 7.4) is a potent buffer. Low-buffering crystalloid solutions cannot prevent a sustained drop in myocardial pH, which can eventually fall as low as 6.54. In contrast, blood-pumping fluid or histidine-buffered HTK solutions, with their high buffering capacity, can effectively maintain myocardial pH above 7.20, preventing serious consequences. Furthermore, an inappropriate alkaline environment has also been shown to fail to enhance protective efficacy.

[0051] (4) Magnesium ions (Mg 2+ Imbalances in the body's calcium levels can lead to arrhythmias and damage to contractile proteins. Magnesium plays a protective role; as a natural calcium antagonist, magnesium supplementation can stabilize cell membranes and control calcium ion influx. Magnesium deficiency in the cardioplegic solution directly leads to postoperative hypomagnesemia, which increases the incidence of postoperative atrial fibrillation, significantly increases the risk of ventricular arrhythmias (such as premature ventricular contractions), and induces perioperative myocardial ischemia and electrocardiographic changes.

[0052] The above are merely optional embodiments of the present invention and do not limit the patent scope of the present invention. All equivalent structural transformations made using the contents of the present invention specification and drawings under the inventive concept of the present invention, or direct / indirect applications in other related technical fields, are included within the patent protection scope of the present invention.

Claims

1. A device for monitoring the injection of stop-jump fluid, characterized in that, The stop-jump fluid infusion monitoring device includes: A cardioplegic solution infusion line, wherein the inlet of the cardioplegic solution infusion line is adapted to receive cardioplegic solution, and the outlet of the cardioplegic solution infusion line is adapted to be inserted into the heart; A stop-pump fluid return line, wherein the input end of the stop-pump fluid return line is adapted to communicate with the heart chamber; A membrane oxygenator, wherein the output end of the stop-shutdown fluid return line is connected to the membrane oxygenator; A first detection sensor is disposed on the cardioplegic solution infusion line, and the first detection sensor is used to detect the components of the cardioplegic solution delivered to the heart; and The second detection sensor is located on the stop-beat fluid return line and is used to detect the components of the stop-beat fluid drained from the heart chambers.

2. The stop-jump fluid infusion monitoring device as described in claim 1, characterized in that, The stop-jump fluid infusion monitoring device further includes a first display, which is electrically connected to the first detection sensor and is used to display stop-jump fluid composition information.

3. The stop-jump fluid infusion monitoring device as described in claim 2, characterized in that, The stop-jump fluid infusion monitoring device also includes a second display, which is electrically connected to the second detection sensor and is used to display stop-jump fluid composition information.

4. The stop-jump fluid infusion monitoring device as described in claim 1, characterized in that, The stop-jump fluid return line includes a return conduit and a balloon located at the inlet end of the return conduit, the balloon being used to prevent blood from flowing out of the coronary sinus.

5. The stop-jump fluid infusion monitoring device as described in claim 4, characterized in that, The reflux conduit is provided with a reflux channel and an inflation channel separated from the reflux channel. The distal end of the inflation channel is connected to the balloon, and the proximal end of the inflation channel is adapted to introduce fluid. or The stop-jump fluid return line also includes a filling conduit, which is disposed close to the return conduit. The distal end of the filling conduit is connected to the balloon, and the proximal end of the filling conduit is adapted to allow fluid to enter.

6. The stop-jump fluid infusion monitoring device as described in claim 5, characterized in that, The stop-jump fluid return line also includes a fluid container connected to the filling channel or the filling conduit.

7. The stop-jump fluid injection monitoring device as described in claim 1, characterized in that, Both the first detection sensor and the second detection sensor are blood gas monitors.

8. The stop-jump fluid perfusion monitoring device as described in any one of claims 1-7, characterized in that, The stop-jump fluid injection monitoring device also includes a temperature controller, which is located on the stop-jump fluid injection pipeline and is used to adjust the temperature of the stop-jump fluid.

9. The stop-jump fluid perfusion monitoring device as described in any one of claims 1-7, characterized in that, The stop-jump fluid injection monitoring device also includes a peristaltic pump, which is located on the stop-jump fluid injection pipeline and is used to drive the flow of the stop-jump fluid.

10. A monitoring method for a stop-jump fluid perfusion monitoring device, based on the stop-jump fluid perfusion monitoring device as described in any one of claims 1-9, characterized in that, The monitoring method includes the following steps: The composition of the liquid in the stop-jump fluid injection line is detected and generated as the first liquid composition information; The composition of the liquid in the stop-shutdown fluid return line is detected and a second liquid composition information is generated. Compare the first liquid composition information with the second liquid composition information to determine whether at least one of the components of the stop-jump fluid is within the target range value; An alarm signal is output when at least one of the components of the stop-jump fluid is not within the target range.

Images